New guideline urges earlier referral for pediatric liver transplant
-
July 21
New recommendations emphasize earlier referral, standardized multidisciplinary evaluation, equitable organ access and disease-specific transplant decision-making.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, describe characteristic cyst findings on cross-sectional and endoscopic sonographic imaging, fluid analysis results, and management.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Motility MRI score may change how clinicians read small bowel Crohn's disease, study finds
-
by Olivia Anderson
A quantitative motility score changed clinician impressions in 47% of cases and reversed them in 22%, but did not alter treatment decisions, the CONTEXT study found.
New guideline urges earlier referral for pediatric liver transplant
-
by Doug Brunk
New recommendations emphasize earlier referral, standardized multidisciplinary evaluation, equitable organ access and disease-specific transplant decision-making.
Home calprotectin monitoring fails to reduce ulcerative colitis flares
-
by Doug Brunk
Proactive home monitoring alone didn't prevent flares, but the authors say pairing it with a standardized escalation protocol warrants further study.
Repeat stool-based screening rates vary widely by health system, study finds
-
by Meg Barbor
In a retrospective cohort of nearly 500,000 adults, consistent repeat stool-based screening ranged from 5% to 61% across four health systems and was tied to earlier-stage cancer at diagnosis.
GLP-1 drugs don't lower IBD relapse but appear safe, study finds
-
by Olivia Anderson
A large target trial emulation found semaglutide and tirzepatide did not reduce one-year relapse rates in patients with stable inflammatory bowel disease, though both appeared safe in those with obesity or diabetes.
